Concepedia

Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study

S. Bakchine, Henrik Loft

Journal of Alzheimer s Disease · 2008 · 85 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist currently approved for the treatment of moderate to severe Alzheimer's disease (AD). A 24-week, double-blind, placebo-controlled, study (Study 99679) conducted in Europe evaluat

References

10

A new rating scale for Alzheimer's disease

Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis · American Journal of Psychiatry · 1984 · 4.1K citations

, , +14

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 2011 · 1.5K citations · Full text

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Martin R. Farlow, Ravi Anand, John Messina et al. · European Neurology · 2000 · 327 citations

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial

Elaine R. Peskind, Steven G. Potkin, Nunzio Pomara et al. · American Journal of Geriatric Psychiatry · 2006 · 301 citations

, , +11

A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease

‌Barry Reisberg, Rachelle S. Doody, Albrecht Stöffler et al. · Archives of Neurology · 2006 · 180 citations